New Insights on Adenovirus As Vaccine Vectors

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2009 Jun 11

PMID 19513019

Citations 132

Authors

Marcio O Lasaro

Hildegund C J Ertl

Affiliations

Soon will be listed here.

Abstract

Adenovirus (Ad) vectors were initially developed for treatment of genetic diseases. Their usefulness for permanent gene replacement was limited by their high immunogenicity, which resulted in rapid elimination of transduced cells through induction of T and B cells to antigens of Ad and the transgene product. The very trait that excluded their use for sustained treatment of genetic diseases made them highly attractive as vaccine carriers. Recently though results showed that Ad vectors based on common human serotypes, such as serotype 5, may not be ideal as vaccine carriers. A recently conducted phase 2b trial, termed STEP trial, with an AdHu5-based vaccine expressing antigens of human immunodeficiency virus 1 (HIV-1) not only showed lack of efficacy in spite of the vaccine's immunogenicity, but also suggested an increased trend for HIV acquisition in individuals that had circulating AdHu5 neutralizing antibodies prior to vaccination. Alternative serotypes from humans or nonhuman primates (NHPs), to which most humans lack pre-existing immunity, have been vectored and may circumvent the problems encountered with the use of AdHu5 vectors in humans. In summary, although Ad vectors have seen their share of setbacks in recent years, they remain viable tools for prevention or treatment of a multitude of diseases.

Citing Articles

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Chekaoui A, Garofalo M, Gad B, Staniszewska M, Chiaro J, Pancer K Clin Exp Med. 2024; 25(1):24.

PMID: 39720956 PMC: 11669620. DOI: 10.1007/s10238-024-01541-7.

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.

Park A, Lee J J Microbiol. 2024; 62(7):491-509.

PMID: 39037484 DOI: 10.1007/s12275-024-00159-4.

Possibilities and efficiency of MSC co-transfection for gene therapy.

Christoffers S, Seiler L, Wiebe E, Blume C Stem Cell Res Ther. 2024; 15(1):150.

PMID: 38783353 PMC: 11119386. DOI: 10.1186/s13287-024-03757-6.

Conditional splicing system for tight control of viral overlapping genes.

Yang Q, Wang J, Chen Z J Virol. 2024; 98(4):e0024224.

PMID: 38446633 PMC: 11019872. DOI: 10.1128/jvi.00242-24.

Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges.

Hahn R, Avraham K Audiol Res. 2023; 13(6):952-966.

PMID: 38131808 PMC: 10740825. DOI: 10.3390/audiolres13060083.

References

Vellinga J, Van der Heijdt S, Hoeben R . The adenovirus capsid: major progress in minor proteins. J Gen Virol. 2005; 86(Pt 6):1581-1588. DOI: 10.1099/vir.0.80877-0. View

Waddington S, McVey J, Bhella D, Parker A, Barker K, Atoda H . Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008; 132(3):397-409. DOI: 10.1016/j.cell.2008.01.016. View

Appaiahgari M, Saini M, Rauthan M, Jyoti , Vrati S . Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect. 2005; 8(1):92-104. DOI: 10.1016/j.micinf.2005.05.023. View

Prasad S, Norbury C, Chen W, Bennink J, Yewdell J . Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol. 2001; 166(8):4809-12. DOI: 10.4049/jimmunol.166.8.4809. View

Nicol C, Graham D, Miller W, White S, Smith T, Nicklin S . Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther. 2004; 10(2):344-54. DOI: 10.1016/j.ymthe.2004.05.020. View

Nicklin S, Wu E, Nemerow G, Baker A . The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther. 2005; 12(3):384-93. DOI: 10.1016/j.ymthe.2005.05.008. View

Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y . Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res. 2008; 14(8):2450-7. DOI: 10.1158/1078-0432.CCR-07-4596. View

Hidaka C, Milano E, Leopold P, Bergelson J, Hackett N, Finberg R . CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest. 1999; 103(4):579-87. PMC: 408101. DOI: 10.1172/JCI5309. View

Pruzan R, Flint S . Transcription of adenovirus RNA polymerase III genes. Curr Top Microbiol Immunol. 1995; 199 ( Pt 1):201-26. DOI: 10.1007/978-3-642-79496-4_11. View

10.

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

11.

Barefoot B, Thornburg N, Barouch D, Yu J, Sample C, Johnston R . Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine. 2008; 26(48):6108-18. PMC: 2646904. DOI: 10.1016/j.vaccine.2008.09.007. View

12.

Benihoud K, Yeh P, Perricaudet M . Adenovirus vectors for gene delivery. Curr Opin Biotechnol. 1999; 10(5):440-7. DOI: 10.1016/s0958-1669(99)00007-5. View

13.

Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, Jackson D . Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. Clin Immunol. 2008; 128(3):329-39. DOI: 10.1016/j.clim.2008.04.002. View

14.

Draper S, Moore A, Goodman A, Long C, Holder A, Gilbert S . Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008; 14(8):819-21. PMC: 4822545. DOI: 10.1038/nm.1850. View

15.

Fallaux F, Bout A, van der Velde I, van den Wollenberg D, Hehir K, Keegan J . New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998; 9(13):1909-17. DOI: 10.1089/hum.1998.9.13-1909. View

16.

Marzio G, Kerkvliet E, Bogaards J, Koelewijn S, de GROOT A, Gijsbers L . A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells. Vaccine. 2007; 25(12):2228-37. DOI: 10.1016/j.vaccine.2006.12.011. View

17.

Butterfield L, Comin-Anduix B, Vujanovic L, Lee Y, Dissette V, Yang J . Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008; 31(3):294-309. PMC: 3651040. DOI: 10.1097/CJI.0b013e31816a8910. View

18.

Liu J, Ewald B, Lynch D, Denholtz M, Abbink P, Lemckert A . Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol. 2008; 82(10):4844-52. PMC: 2346755. DOI: 10.1128/JVI.02616-07. View

19.

Liu J, OBrien K, Lynch D, Simmons N, La Porte A, Riggs A . Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2008; 457(7225):87-91. PMC: 2614452. DOI: 10.1038/nature07469. View

20.

Calcedo R, Vandenberghe L, Roy S, Somanathan S, Wang L, Wilson J . Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol. 2009; 83(6):2623-31. PMC: 2648267. DOI: 10.1128/JVI.02160-08. View